Skip to main content
Top
Published in: Drug Safety 11/2010

01-11-2010 | Original Research Article

Preventability of Drug-Related Harms — Part II

Proposed Criteria, Based on Frameworks that Classify Adverse Drug Reactions

Authors: Dr Jeffrey K. Aronson, Robin E. Ferner

Published in: Drug Safety | Issue 11/2010

Login to get access

Abstract

Background: ‘Preventability’ is a crucial concept in the literature on adverse drug effects. However, a systematic review of the definitions of preventability of adverse drug effects has suggested that none fits all circumstances. Furthermore, when the reliability of these definitions has been examined they have been found to be imperfect.
Objective: To propose and outline a method for determining the theoretical preventability of an adverse drug effect, based on frameworks for classifying adverse drug reactions — the EIDOS and DoTS methods.
Methods: EIDOS is based on the mechanism of action of the drug. It observes that a drug (an Extrinsic species) causes an adverse effect by interacting with an Intrinsic species that is its target when the two are Distributed together, and that the resulting pathophysiological Outcome (the adverse effect) causes the Sequela (the adverse reaction).
DoTS observes that the Dose-relatedness of the adverse effect compared with the beneficial effect is relevant (determining toxic, collateral, or hypersusceptibility effects), that adverse effects have Time-courses (varying from immediate to delayed), and that there are individual Susceptibility factors.
Results and Discussion: We have elicited many published examples that show that each of these factors in the causation of an adverse drug effect can be adduced to assess its preventability. We have constructed a flowchart that illustrates how the processes can be logically analysed.
Conclusions: This approach suggests methods for devising prospective preventive strategies and for deciding retrospectively whether an adverse reaction in an individual should have been prevented.
Footnotes
1
A chemical species is “a particular kind of molecule, ion, free radical, etc.” (Oxford English Dictionary)
 
Literature
1.
go back to reference Olivier P, Caron J, Haramburu F, et al. Validation d’une éhelle de mesure: exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Thérapie 2005; 60(1): 39–45PubMedCrossRef Olivier P, Caron J, Haramburu F, et al. Validation d’une éhelle de mesure: exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Thérapie 2005; 60(1): 39–45PubMedCrossRef
2.
go back to reference Ferner RE, Aronson JK. Preventability of drug-related harms-part I: a systematic review. Drug Saf 2010; 33(11): 985–94PubMedCrossRef Ferner RE, Aronson JK. Preventability of drug-related harms-part I: a systematic review. Drug Saf 2010; 33(11): 985–94PubMedCrossRef
3.
go back to reference Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug Saf 2010; 33(1): 15–23PubMedCrossRef Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug Saf 2010; 33(1): 15–23PubMedCrossRef
4.
go back to reference Howick J, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. J R Soc Med. In press Howick J, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. J R Soc Med. In press
5.
go back to reference Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115(4): 1048–57PubMedCrossRef Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115(4): 1048–57PubMedCrossRef
6.
go back to reference Simat TJ, Kleeberg KK, M;uller B, et al. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 1999; 467: 469–80PubMedCrossRef Simat TJ, Kleeberg KK, M;uller B, et al. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 1999; 467: 469–80PubMedCrossRef
7.
go back to reference Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D 2007; 8(5): 301–14PubMedCrossRef Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D 2007; 8(5): 301–14PubMedCrossRef
8.
go back to reference Montoliu J, Carrera M, Darnell A, et al. Lactic acidosis and Fanconi’s syndrome due to degraded tetracycline. Br Med J (Clin Res Ed) 1981; 283(6306): 1576–7CrossRef Montoliu J, Carrera M, Darnell A, et al. Lactic acidosis and Fanconi’s syndrome due to degraded tetracycline. Br Med J (Clin Res Ed) 1981; 283(6306): 1576–7CrossRef
10.
go back to reference Shaw IC, Rose JWP. Infusion of ifosphamide plus mesna. Lancet 1984; I(8390): 1353–4CrossRef Shaw IC, Rose JWP. Infusion of ifosphamide plus mesna. Lancet 1984; I(8390): 1353–4CrossRef
11.
go back to reference Ben Abraham R, Adnet P, Glauber V, et al. Malignant hyperthermia. Postgrad Med J 1998; 74(867): 11–7PubMedCrossRef Ben Abraham R, Adnet P, Glauber V, et al. Malignant hyperthermia. Postgrad Med J 1998; 74(867): 11–7PubMedCrossRef
12.
go back to reference Marsh S, Van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 2009; 85(2): 139–41PubMedCrossRef Marsh S, Van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 2009; 85(2): 139–41PubMedCrossRef
13.
go back to reference Phillips EJ, Mallal SA. HLA and drug-induced toxicity. Curr Opin Mol Ther 2009; 11(3): 231–42PubMed Phillips EJ, Mallal SA. HLA and drug-induced toxicity. Curr Opin Mol Ther 2009; 11(3): 231–42PubMed
14.
go back to reference SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359(8): 789–99PubMedCrossRef SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359(8): 789–99PubMedCrossRef
15.
go back to reference McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332(7551): 1177–81PubMedCrossRef McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332(7551): 1177–81PubMedCrossRef
16.
go back to reference Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991; 164: 1180–5PubMedCrossRef Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991; 164: 1180–5PubMedCrossRef
17.
go back to reference Martin J, editor. British national formulary. No. 57. Section 4.7.3. Trigeminal neuralgia. London: BMJ Group and RPS Publications, 2009 Martin J, editor. British national formulary. No. 57. Section 4.7.3. Trigeminal neuralgia. London: BMJ Group and RPS Publications, 2009
18.
go back to reference Slome R. Withdrawal of propranolol and myocardial infarction. Lancet 1973; I(7795): 156CrossRef Slome R. Withdrawal of propranolol and myocardial infarction. Lancet 1973; I(7795): 156CrossRef
20.
go back to reference Peto R. Influence of dose and duration of smoking on lung cancer rates. IARC Sci Publ 1986; (74): 23–33 Peto R. Influence of dose and duration of smoking on lung cancer rates. IARC Sci Publ 1986; (74): 23–33
21.
22.
go back to reference Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851–70PubMedCrossRef Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851–70PubMedCrossRef
23.
go back to reference Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222–5PubMedCrossRef Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222–5PubMedCrossRef
24.
go back to reference Bareggi SR, Tata MR, Guizzaro A, et al. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Int Clin Psychopharmacol 1994; 9(1): 9–16PubMedCrossRef Bareggi SR, Tata MR, Guizzaro A, et al. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Int Clin Psychopharmacol 1994; 9(1): 9–16PubMedCrossRef
25.
go back to reference Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326(7404): 1419–23PubMedCrossRef Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326(7404): 1419–23PubMedCrossRef
26.
go back to reference Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005; 65(4): 525–7PubMedCrossRef Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005; 65(4): 525–7PubMedCrossRef
27.
go back to reference Khoo SH, Bond J, Denning DW. Administering amphotericin B: a practical approach. J Antimicrob Chemother 1994; 33(2): 203–13PubMedCrossRef Khoo SH, Bond J, Denning DW. Administering amphotericin B: a practical approach. J Antimicrob Chemother 1994; 33(2): 203–13PubMedCrossRef
Metadata
Title
Preventability of Drug-Related Harms — Part II
Proposed Criteria, Based on Frameworks that Classify Adverse Drug Reactions
Authors
Dr Jeffrey K. Aronson
Robin E. Ferner
Publication date
01-11-2010
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 11/2010
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11538280-000000000-00000

Other articles of this Issue 11/2010

Drug Safety 11/2010 Go to the issue